Compare EPAM Systems Inc (EPAM) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPAM Systems Inc vs TransMedics Group Inc — how do they compare? EPAM Systems Inc trades at $113.68 (market cap $5.87B), while TransMedics Group Inc trades at $77.5 (market cap $2.74B). The key difference: EPAM Systems Inc is far larger — about 2.1× TransMedics Group Inc's market cap, and TransMedics Group Inc is more actively traded (949,331 versus 847,420). Which is the better fit depends on your goals — on Pluang, investors hold EPAM Systems Inc for 37 Days and TransMedics Group Inc for 24 Days on average.
| EPAM | TMDX | |
|---|---|---|
Market Cap | $5.87B | $2.74B |
Volume | 847,420 | 949,331 |
Sector | Technology | Health |
52-Week High | $221.40 | $150.42 |
52-Week Low | $76.04 | $61.99 |
Typical Hold Time | 37 Days | 24 Days |
Enterprise Value | $5.24B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPAM Systems trades at $113.54, up 4.82% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a consensus price target of $119 suggest upside potential. The company reported $5.46B in 2025 revenue, with a net income margin of 7.15%, while maintaining solid cash flow from operations of $654.93M.
The outlook is positive, driven by AI-native revenue growth exceeding 11% and activist shareholder pressure for buybacks. Risks include slower North American growth and competitive pressures in digital transformation services. The stock's current valuation at a P/E of 15.45 appears reasonable relative to earnings growth prospects.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
